

Tethered Silanoxyiodination of Alkenes

Ranjeet A. Dhokale, Frederick J. Seidl, Anand H. Shinde, Joel T. Mague, and Shyam Sathyamoorthi*

Cite This: J. O	rg. Chem. 2021, 86, 9233–9243	Read Online
ACCESS	III Metrics & More	Article Recommendations Supporting Information

ABSTRACT: We present the first examples of tethered silanoxyiodination reactions of allylic alcohols. The products are useful silanediol organoiodide synthons and are formed with high regioselectivity and diastereocontrol. The reaction is scalable greater than 10-fold without loss of yield or selectivity. Furthermore, the products are starting materials for further transformations, including deiodination, C–N bond installation, epoxide synthesis, and desilylation. DFT calculations provide a basis for understanding the exquisite 6-endo selectivity of this silanoxyiodination reaction and show that the observed products are both kinetically and thermodynamically preferred.



T ethered alkene functionalization reactions allow the synthetic chemist to transform olefins with unusual precision.¹⁻⁷ Because of the predisposition for six- and sevenmembered cyclic transition states, one can simply count the number of atoms from the nucleophilic auxiliary ("the tether") where the functionalization event is likely to take place; due to geometric constraints, these reactions generally proceed with high regio- and diastereoselectivity. Our laboratory is deeply invested in developing tethered olefin functionalization reactions, and we have disclosed such reactions using sulfamate,^{8,9} phosphoramidate,¹⁰ and di-*tert*-butylsilanoxy tethers.^{11,12}

Iodofunctionalization of olefins is a particularly powerful method for the synthesis of organoiodides, which are versatile precursors for C–O,¹³ C–N,¹⁴ and C–C bonds¹⁵ (Scheme 1).





Two particularly well-known classes within this large area are iodolactonization¹⁶⁻²⁰ and iodoetherification²¹⁻²⁴ of olefins (Scheme 2), and examples of both are found in complex molecule syntheses. Building on this precedent, we imagined a silanoxyiodination reaction that would yield protected diol iodides in a single step and with high regio- and diastereoselectivity. We reasoned that the di-*tert*-butyl silyl group could be facilely removed to reveal useful iodo-diol

Scheme 2. Elegant Work with Iodolactonization and Iodoetherification Inspired This Tethered Silanoxyiodination



synthons. Here, we describe our efforts to reduce this idea to practice.

Received: April 15, 2021 **Published:** June 15, 2021





Optimization of this tethered silanoxyiodination reaction began with (*E*)-di-*tert*-butyl(hex-2-en-1-yloxy)silanol, conveniently prepared in one step from commercially available di-*tert*butylsilyl bis(trifluoromethanesulfonate) and *trans*-2-hexen-1ol.¹¹ With I₂ (3 equiv) and NaHCO₃ (6 equiv) in acetonitrile at 0 °C, we were pleased to observe 65% of desired product (Table 1, entry 1). However, we soon discovered that these

Table 1. Optimization of a Tethered Silanoxyiodination Reaction



^{*a*}Reaction times were between 1 and 2 h in all cases. ^{*b*}Yield estimated from ¹H NMR integration with methyl phenyl sulfone as an internal standard. ^{*c*}With 6 equiv of NaHCO₃. ^{*d*}Two noncyclized products, which we presume result from NO₃⁻ opening of the iodonium intermediate. ^{*c*}Two noncyclized products, which we presume result from CF₃CO₂⁻ opening of the iodonium intermediate.

conditions were much too corrosive with other allylic silanols and led to markedly reduced product yields. The use of Ag (I) in conjunction with I₂ is well-known for the mild generation of $I^{+,\,21,23,25}$ With AgNO $_3/I_2$ (Table 1, entry 2) and with $Ag(TFA)/I_2$ (Table 1, entry 3) we did not observe any cyclized product formation. In both cases, we isolated linear alkyl iodide products, which we presume result from intermolecular opening of the transient iodonium intermediate by NO_3^- and $CF_3CO_2^-$. We hypothesized that switching to a silver salt with a non-nucleophilic counterion would eliminate intermolecular ring-opening. With AgBF₄ in acetonitrile, tetrahydrofuran, or ethyl acetate (Table 1, entries 4-6) at 0 °C, we observed ~60% cyclized product formation. Using CH₂Cl₂ as a solvent was markedly deleterious (Table 1, entry 7). In THF, when the temperature was reduced from 0 to -15°C, the yield of cyclized product increased slightly (Table 1, entry 8); however, dropping the temperature further to -45°C led to a dramatic decrease in product formation (Table 1, entry 9). We found that $Ag(OTf)/I_2$ in THF, $Ag(OTf)/I_2$ in DME, and $AgBF_4/I_2$ in DME at -15 °C (Table 1, entries 10-12) all gave comparable, good yields of cyclized product. Overall, we chose three protocols (A: AgBF₄/I₂/THF, B: AgBF₄/I₂/DME, C: AgOTf/I₂/DME) for further exploration of scope.

Examination of a variety of allylic silanol substrates (Scheme 3) with these protocols revealed that this transformation is quite general, tolerant of diverse functional groups, and in most

cases proceeds with high regio- and diastereoselectivity. We have determined the relative configuration of one of these products through X-ray diffraction analysis, which establishes that the iodine and the pendant alkyl chain are trans to each other (Scheme 3, entry 11, CCDC: 2062814). While protocol A $(AgBF_4/I_2/THF)$ gave good product yields with several substrates (Scheme 3, entries 1 and 7), a curious side product complicated crude NMR analysis and purification. Amazingly, this side product has been previously characterized and arises from a ring-opening polymerization of THF by I₂!²⁶ We thus abandoned THF in favor of DME, and we recommend that for substrates not shown here both protocol B $(AgBF_4/I_2/DME)$ and protocol C (AgOTf/I2/DME) should be empirically tested for best results. We were pleased to find that a variety of alkyl chains (Scheme 3, entries 1, 2, and 6), rings (Scheme 3, entries 3 and 4), alkyl ethers (Scheme 3, entry 3), ketals (Scheme 3, entry 5), esters (Scheme 3, entry 10), aromatic rings (Scheme 3, entries 8 and 11), and heteroaromatic rings (Scheme 3, entries 9 and 12) were all tolerated by our optimized protocols. Furthermore, we were not limited to disubstituted olefins. A variety of trisubstituted olefins (Scheme 3, entries 13–15) reacted smoothly as well.

We were pleased to see that the reaction scaled greater than 10-fold without loss of yield or selectivity (Scheme 4).

Furthermore, the cyclic silanediol organoiodide products were amenable to a variety of further transformations, including deiodination, nucleophilic azide displacement, epoxide formation, and silicon removal (Scheme 5).

In all cases, we exclusively observed products of 6-endo-trig cyclization reactions. In order to rationalize such exquisite selectivity for the 6-endo product over the 5-exo isomer, we turned to DFT calculations using the ORCA software package.^{27,28} All calculations were performed using the B3LYP functional^{29,30} with D3BJ dispersion correction^{31,32} using the RIJCOSX approximation.³³ The def2-TZVP basis set³⁴ was used, and implicit THF solvation was applied using the SMD model.³⁵ When iodine was present, the def2-ECP³⁶ was applied automatically. Counterions were not modeled for ionic species. Further details and atomic coordinates are reported in the Supporting Information.

Upon exposing substrate alkene 1 to molecular iodine, the immediate product is an intermediate iodonium 61. Intramolecular ring closure can proceed via either a 5-exo (62) or a 6-endo (63) transition state, leading to isomeric protonated products 64 and 65. For the 5-exo pathway, both the transition state and the cationic product are more than 4 kcal/mol higher in energy than their 6-endo counterparts (Figure 1). This overwhelming preference for the 6-endo pathway agrees with the experimental absence of any 5-exo product, even in trace amounts. The origin of the 6-endo selectivity is most likely due to ring strain. For acyclic iodonium 61, the O-Si-O angle is 102.6° , which is 6.9° lower than the ideal tetrahedral angle of 109.5°. This initial acyclic perturbation is likely due to the presence of the tert-butyl groups on the silicon, a manifestation of the Thorpe-Ingold effect.³⁷ The 6-endo transition state 63 has an O-Si-O angle of 101.3° and the 6-endo product 65 has an O-Si-O angle of 97.6°, the latter of which is only 5° smaller than the acyclic angle on iodonium 61. By contrast, the 5-exo transition state 62 has an O-Si-O angle of 96.7° and the 5-exo product 64 has an O-Si-O angle of 89.8°, the latter of which is now geometrically acute and 12.8° smaller than the acyclic angle on iodonium 61. Thus, the tert-butyl groups on silicon promote a Si-O-Si angle close to that required for 6-

Scheme 3. Substrate Scope



Scheme 4. Silanoxyiodination Scales Greater than 10-Fold without Loss of Yield or Selectivity



endo ring closure, while 5-exo ring closure requires a much more strained and energetically unfavorable Si-O-Si angle.

In summary, we present the first examples of tethered silanoxyiodination reactions of allylic alcohols. The products are useful silanediol organoiodide synthons and are formed with high regioselectivity and diastereocontrol. The reaction is scalable greater than 10-fold without loss of yield or selectivity. Furthermore, the products are starting materials for further Scheme 5. Products Are Versatile Synthons for (A) Deiodination, (B) C–N Bond Formation, (C) Epoxide Formation, and (D) Silicon Removal



Figure 1. DFT energies for cationic iodonium rearrangements of substrate 1.

transformations, including deiodination, C–N bond installation, epoxide synthesis, and desilylation. DFT calculations provide a basis for understanding the exquisite 6-endo selectivity of this silanoxyiodination reaction. We expect this reaction to find much use in the construction of complex molecules containing functional group stereochemical arrays.

EXPERIMENTAL SECTION

I. General Considerations. All reagents were obtained commercially unless otherwise noted. Solvents were purified by passage under 10 psi N_2 through activated alumina columns. Infrared (IR) spectra were recorded on a Thermo Scientific Nicolet iSS FT-IR spectrometer; data are reported in frequency of absorption (cm⁻¹). NMR spectra were recorded on a Bruker Avance 400 operating at 400

and 100 MHz. ¹H NMR spectra were recorded at 400 MHz. Data are recorded as chemical shift in ppm referenced internally using residue solvent peaks, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet or overlap of nonequivalent resonances), integration, and coupling constant (Hz). ¹³C NMR spectra were recorded at 100 MHz. Exact mass spectra were recorded using an electrospray ion source (ESI) either in positive mode or negative mode with a time-of-flight (TOF) analyzer on a Waters LCT PremierTM mass spectrometer and are given in *m/z*. TLC was performed on precoated glass plates (Merck) and visualized either with a UV lamp (254 nm) or by dipping into a solution of KMnO₄– K₂CO₃ in water followed by heating. Flash chromatography was performed on silica gel (230–400 mesh) or Florisil (60–100 mesh).

II. Characterization of Previously Unreported Substrates. Note 1: Substrates were synthesized according to previously reported procedures.¹¹ Note 2: Compounds 1–4, 6–8, 11, 13–17, 19, 20, 23, and 25 have been reported previously.^{11,12}.



(*E*)-*Di*-tert-butyl((6-methylhept-2-en-1-yl)oxy)silanol (5). Purified using a gradient of 0–10% EtOAc in hexanes on silica gel (yellow oil, 476 mg, 83%); ¹H NMR (400 MHz, chloroform-*d*) δ 5.69 (ddt, *J* = 14.1, 6.2, 1.2 Hz, 1H), 5.59 (dtt, *J* = 15.3, 5.3, 1.2 Hz, 1H), 4.35–4.28 (m, 2H), 2.12–2.01 (m, 2H), 1.58 (dq, *J* = 13.3, 6.7 Hz, 1H), 1.33–1.24 (m, 2H), 1.05 (s, 18H), 0.91 (d, *J* = 6.6 Hz, 6H); ¹³C{¹H} NMR (101 MHz, chloroform-*d*) δ 131.6, 129.1, 64.2, 38.4, 30.0, 27.5, 27.42, 22.47, 20.46; IR 2857, 1457, 1173 cm⁻¹; HRMS (ESI) calcd for C₁₆H₃₃O₂Si⁻ 285.2250, found 285.2245 (M⁻).



(*E*)-*Di*-tert-butyl((3-(tetrahydro-2H-pyran-4-yl)allyl)oxy)silanol (**9**). Purified using a gradient of 0 to 50% acetone/DCM; (light yellow oil, 403 mg, 67% yield); ¹H NMR (400 MHz, CDCl₃) δ 5.63–5.54 (m, 1H), 5.54–5.42 (m, 1H), 4.24 (tt, *J* = 4.8, 1.2 Hz, 2H), 3.89 (ddt, *J* = 12.5, 4.2, 1.6 Hz, 2H), 3.35 (tt, *J* = 11.6, 2.2 Hz, 2H), 2.20–2.12 (m, 1H), 1.55 (ddq, *J* = 12.8, 4.1, 2.0 Hz, 2H), 1.46–1.30 (m, 2H), 0.95 (s, 18H); ¹³C{¹H} NMR (101 MHz, CDCl₃) δ 134.8, 134.4, 127.9, 127.6, 67.7, 64.1, 63.9, 37.3, 32.6, 32.5, 27.8, 27.4, 21.2, 20.4; IR 2933, 1473, 1127, 827, 648 cm⁻¹; HRMS (ESI) calcd for C₁₆H₃₁O₃Si⁻ 299.2048, found 299.2055 (M⁻).



tert-Butyl (*E*)-4-(3-((*di-tert-butyl*(*hydroxy*)*silyl*)*oxy*)*prop-1-en-1-yl*)*piperidine-1-carboxylate* (**10**). Purified using a gradient of 0–10% EtOAc in hexanes on silica gel (colorless oil, 663 mg, 83%); ¹H NMR (400 MHz, chloroform-*d*) δ 5.70–5.55 (m, 2H), 4.33 (dd, *J* = 4.8, 1.2 Hz, 2H), 4.11 (dt, *J* = 13.7, 3.6 Hz, 2H), 2.76 (ddd, *J* = 13.3, 12.2, 2.8 Hz, 2H), 2.14 (td, *J* = 10.8, 5.9 Hz, 1H), 1.74–1.65 (m, 2H), 1.48 (s, 9H), 1.37–1.25 (m, 2H), 1.05 (s, 18H); ¹³C{¹H} NMR (101 MHz, chloroform-*d*) δ 154.9, 134.6, 128.0, 79.3, 63.9, 43.6, 38.4, 31.7, 28.4, 27.4, 20.4; IR 2857, 1457, 1173 cm⁻¹; HRMS (ESI) calcd for C₂₁H₄₁NO₄SiNa⁺ 422.2703, found mass 422.2692 (MNa⁺).



(*S*,*E*)-((*3*-(1,*4*-*Dioxaspiro*[*4*.5]*decan*-2-*y*)/*a*ll*y*])*oxy*)*di*-tert-buty|*si*-lanol (12). Purified using a gradient of 0–20% EtOAc/hexanes (colorless oil, 420 mg, 59% yield); ¹H NMR (400 MHz, CDCl₃) δ 5.92 (dtd, *J* = 15.3, 4.5, 0.9 Hz, 1H), 5.75 (ddt, *J* = 15.4, 7.4, 1.7 Hz, 1H), 4.62–4.50 (m, 1H), 4.39 (ddd, *J* = 4.5, 1.7, 0.7 Hz, 2H), 4.14–4.09 (m, 1H), 3.68–3.53 (m, 1H), 1.72–1.58 (m, 9H), 1.43 (m, 1H), 1.05 (s, 18H); ¹³C{¹H} NMR (101 MHz, CDCl₃) δ 133.4, 127.4, 109.8, 76.2, 69.1, 63.0, 36.2, 35.4, 27.4, 25.1, 23.9, 23.8, 20.5; IR 2866, 1465, 1082, 829 cm⁻¹; HRMS (ESI) calcd for C₁₉H₃₅O₄Si⁻ 355.2310, found 355.2336 (M⁻).



(E)-((3-(4-Bromophenyl)allyl)oxy)di-tert-butylsilanol (18). Purified using a gradient of 0–0.2% acetone in DCM (light yellow oil, 319 mg, 43% yield); ¹H NMR (400 MHz, CDCl₃) δ 7.57–7.40 (m, 2H), 7.40–7.16 (m, 2H), 6.61 (dt, *J* = 15.9, 2.0 Hz, 1H), 6.33 (dt, *J* = 15.8, 4.9 Hz, 1H), 4.55 (dd, *J* = 4.9, 1.8 Hz, 2H), 1.09 (d, *J* = 0.9 Hz, 18H); ¹³C{¹H} NMR (101 MHz, CDCl₃) δ 136.2, 131.7, 130.1, 128.2, 128.0, 121.1, 63.9, 27.5, 20.6; IR 3471, 2919, 1479, 1378, 829 cm⁻¹; HRMS (ESI) calcd for C₁₇H₂₆BrO₂Si⁻ 369.0891, found 369.0867 (M⁻).

(*E*)-4-((*Di*-tert-butyl(hydroxy)silyl)oxy)but-2-en-1-yl acetate (**21**). Purified using a gradient of 0–50% acetone in DCM on silica gel followed by a gradient of 0 to 100% acetonitrile in 0.1%TFA/H₂O on a RediSep Prep C18 column (100 Å, 5 μ m, Length 250 mm i.d.: 20 mm, flow rate of 15 mL/min) (light yellow oil, 288 mg, 50% yield); ¹H NMR (400 MHz, CDCl₃) δ 5.96–5.78 (m, 2H), 4.67–4.56 (m, 2H), 4.40 (dt, *J* = 4.0, 1.3 Hz, 2H), 2.10 (s, 3H), 1.06 (s, 18H). ¹³C{¹H} NMR (101 MHz, CDCl₃) δ 171.1, 134.2, 123.3, 64.6, 63.0, 27.4, 20.9, 20.5; IR 3442, 2947, 1730, 1246, 829 cm⁻¹; HRMS (ESI) calcd for C₁₄H₂₇O₄Si⁻ 287.1684, found 287.1661 (M⁻).



(*E*)-4-((*Di*-tert-butyl(hydroxy)silyl)oxy)but-2-en-1-yl benzoate (22). Purified using a gradient of 0–50% acetone/DCM on silica gel (light yellow semisolid, 343 mg, 49% yield); ¹H NMR (400 MHz, CDCl₃) δ 8.09–7.98 (m, 2H), 7.60–7.53 (m, 1H), 7.44 (ddd, *J* = 8.2, 6.7, 1.2 Hz, 2H), 6.03–5.88 (m, 2H), 4.83 (tt, *J* = 2.3, 1.3 Hz, 2H), 4.40 (p, *J* = 1.4 Hz, 2H), 1.03 (s, 18H). ¹³C{¹H} NMR (101 MHz, CDCl₃) δ 166.6, 134.2, 133.0, 130.3, 129.7, 128.4, 123.7, 65.0, 63.2, 27.5, 20.6; IR 3447, 2933, 1704, 1279, 827 cm⁻¹; HRMS (ESI) calcd for C₁₉H₂₉O₄Si⁻ 349.1841, found 349.1813 (M⁻).



(*E*)-*Di*-tert-butyl((3-(pyridin-3-yl)allyl)oxy)silanol (24). Purified using a gradient of 0–10% EtOAc in hexanes on silica gel (colorless oil, 411 mg, 70%); ¹H NMR (400 MHz, chloroform-*d*) δ 8.60 (d, *J* = 2.2 Hz, 1H), 8.47 (dd, *J* = 4.9, 1.6 Hz, 1H), 7.71 (dt, *J* = 7.9, 1.9 Hz, 1H), 7.27 (dd, *J* = 7.9, 4.9 Hz, 1H), 6.65 (dd, *J* = 15.9, 1.8 Hz, 1H), 6.40 (ddd, *J* = 16.0, 5.1, 4.2 Hz, 1H), 4.58 (dd, *J* = 4.7, 1.9 Hz, 2H), 1.10 (s, 18H); ¹³C{¹H} NMR (101 MHz, chloroform-*d*) δ 148.0, 147.9, 133.0, 132.9, 131.9, 125.3, 123.5, 63.6, 27.4, 20.5; IR 2856, 1471, 1134 cm⁻¹; HRMS (ESI) calcd for C₁₆H₂₈NO₂Si⁺ 294.1884 found 294.1852 (MH⁺).



Di-tert-butyl((*3-ethylpent-2-en-1-yl)oxy*)*silanol* (**26**). Purified using a gradient of 0–10% EtOAc in hexanes on silica gel (colorless oil, 409 mg, 75%); ¹H NMR (400 MHz, chloroform-*d*) δ 5.32 (td, *J* = 6.5, 3.3 Hz, 1H), 4.40 (dd, *J* = 6.3, 1.2 Hz, 2H), 2.13–2.01 (m, 4H), 1.08–0.97 (m, 6H),1.05 (s, 18H); ¹³C{¹H} NMR (101 MHz, chloroform-*d*) δ 144.6, 122.7, 60.1, 28.9, 27.4, 23.6, 20.4, 13.3, 12.5; IR 2933, 1471, 1107 cm⁻¹; HRMS (ESI) calcd for $C_{15}H_{31}O_2Si^-$ 271.2093 found 271.2091 (M⁻).



(E)-Di-tert-butyl((3,7,11,15-tetramethylhexadec-2-en-1-yl)oxy)silanol (27). Purified using a gradient of 0–0.1% acetone in DCM (colorless oil, 400 mg, 44% yield); ¹H NMR (400 MHz, CDCl₃) δ 5.37 (tq, *J* = 6.3, 1.3 Hz, 1H), 4.39 (dq, *J* = 6.4, 0.9 Hz, 2H), 2.05– 1.96 (m, 2H), 1.65 (t, *J* = 0.8 Hz, 3H), 1.56 (dp, *J* = 13.3, 6.6 Hz, 1H), 1.49–1.08 (m, 18H), 1.05 (s, 18H), 0.89 (ddd, *J* = 8.5, 6.6, 0.7 Hz, 12H); ¹³C{¹H} NMR (101 MHz, CDCl₃) δ 137.4, 124.3, 60.4, 39.8, 39.3, 37.4, 37.4, 37.3, 36.6, 32.8, 32.7, 27.9, 27.4, 25.1, 24.8, 24.4, 22.7, 22.6, 20.4, 19.7, 19.7, 16.2; IR 2928, 1471, 1364, 1099, 827 cm⁻¹; HRMS (ESI) calcd for C₂₈H₃₈NaO₂Si⁺ 477.4098, found 477.4067 (MNa⁺).



Di-tert-butyl(2-(*tetrahydro-4H-pyran-4-ylidene*)*ethoxy*)*silanol* (28). Purified using a gradient of 0–10% EtOAc in hexanes on silica gel (colorless oil, 401 mg, 70%); ¹H NMR (400 MHz, chloroform-*d*) δ 5.44 (tt, *J* = 6.6, 1.3 Hz, 1H), 4.39 (d, *J* = 6.5 Hz, 2H), 3.71 (dt, *J* = 13.3, 5.5 Hz, 4H), 2.36–2.29 (m, 2H), 2.29–2.22 (m, 2H), 1.98 (s, 1H), 1.05 (s, 18H); ¹³C{¹H} NMR (101 MHz, chloroform-*d*) δ 136.3, 123.1, 69.4, 68.5, 59.1, 36.6, 29.9, 27.3, 20.4; IR 2933, 1471, 1107 cm⁻¹; HRMS (ESI) calcd for C₁₅H₃₀O₃SiNa⁺ 309.1856 found 309.1821 (MNa⁺).

III. General Protocols for Silanoxyiodination of Alkenes. Protocol A. A microwave vial was charged with stir bar, alkene substrate (0.2 mmol, 1 equiv), AgBF₄ (39 mg, 0.2 mmol, 1 equiv), and 2 mL of anhydrous THF. The reaction vial was immersed in a bath set to -15 °C. I₂ (51 mg, 0.2 mmol, 1 equiv) was added in one portion. A light yellow precipitate formed immediately upon addition of AgBF₄. The heterogeneous mixture was stirred for 1 h at -15 °C and then quenched by addition of aqueous saturated Na₂S₂O₃. The reaction mixture was diluted with ethyl acetate and transferred to a separatory funnel. The organic portion was collected, and the aqueous layer was extracted with two additional portions of ethyl acetate. The organic fractions were pooled, dried with MgSO₄, and concentrated under reduced pressure. The resulting residue was purified by chromatography on Florisil (specific conditions are associated with each compound).

Protocol B. A microwave vial was charged with stir bar, alkene substrate (0.2 mmol, 1 equiv), AgBF₄ (39 mg, 0.2 mmol, 1 equiv), and 2 mL of anhydrous DME. The reaction vial was immersed in a bath set to -15 °C. I₂ (51 mg, 0.2 mmol, 1 equiv) was added in one portion. A light-yellow precipitate formed immediately upon addition of AgBF₄. The heterogeneous mixture was stirred for 1 h at -15 °C and then quenched by addition of aqueous saturated Na₂S₂O₃. The reaction mixture was diluted with ethyl acetate and transferred to a separatory funnel. The organic portion was collected, and the aqueous layer was extracted with two additional portions of ethyl acetate. The

organic fractions were pooled, dried with MgSO₄, and concentrated under reduced pressure. The resulting residue was purified by chromatography on Florisil (specific conditions are associated with each compound).

Protocol C. A microwave vial was charged with stir bar, alkene substrate (0.2 mmol, 1 equiv), AgOTf (51 mg, 0.2 mmol, 1 equiv), and 2 mL of anhydrous DME. The reaction vial was immersed in a bath set to -15 °C. I₂ (51 mg, 0.2 mmol, 1 equiv) was added in one portion. A light-yellow precipitate formed immediately upon addition of AgOTf. The heterogeneous mixture was stirred for 1 h at -15 °C and then quenched by addition of aqueous saturated Na₂S₂O₃. The reaction mixture was diluted with ethyl acetate and transferred to a separatory funnel. The organic portion was collected, and the aqueous layer was extracted with two additional portions of ethyl acetate. The organic fractions were pooled, dried with MgSO₄, and concentrated under reduced pressure. The resulting residue was purified by chromatography on Florisil (specific conditions are associated with each compound).

IV. Characterization of lodinated Products.



2,2-Di-tert-butyl-5-iodo-4-methyl-1,3,2-dioxasilinane (**29**). Synthesized using protocol C; single diastereomer; purified using benzene on Florisil (light yellow semisolid, 66 mg, 92% isolated yield); ¹H NMR (400 MHz, CDCl₃) δ 4.31 (dq, J = 10.2, 6.0 Hz, 1H), 4.27–4.16 (m, 2H), 4.01 (td, J = 10.5, 5.2 Hz, 1H), 1.53 (d, J = 6.0 Hz, 3H), 1.07 (s, 9H), 1.01 (s, 9H). ¹³C{¹H} NMR (101 MHz, CDCl₃) δ 75.7, 71.0, 34.2, 27.4, 26.9, 24.8, 22.7, 19.8; IR 2960, 1474, 1136, 825 cm⁻¹; HRMS (ESI) calcd for C₁₂H₂₆IO₂Si⁺ 357.0741, found 357.0740 (MH⁺).



2,2-Di-tert-butyl-5-iodo-4-propyl-1,3,2-dioxasilinane (**30**). Synthesized using protocol A; single diastereomer; light yellow solid; purified using a gradient of 0–10% EtOAc in hexanes on silica gel; 54 mg, 70% isolated yield; ¹H NMR (400 MHz, CDCl₃) δ 4.20–4.09 (m, 2H), 4.05 (ddd, *J* = 10.2, 8.0, 2.2 Hz, 1H), 3.98 (td, *J* = 10.4, 4.9 Hz, 1H), 2.02–1.91 (m, 1H), 1.52–1.32 (m, 3H), 0.97 (s, 9H), 0.91 (s, 9H), 0.88 (t, *J* = 7.2 Hz, 3H); ¹³C{¹H} NMR (101 MHz, CDCl₃) δ 78.3, 71.3, 39.8, 33.2, 27.4, 26.9, 22.8, 19.9, 17.9, 13.7; IR 2960, 1474, 1135, 825 cm⁻¹; HRMS (ESI) calcd for C₁₄H₃₀IO₂Si⁺ 385.1054, found 385.1057 (MH⁺).



2,2-Di-tert-butyl-5-iodo-4-nonyl-1,3,2-dioxasilinane (**31**). Synthesized using protocol A; single diastereomer; purified using benzene on Florisil (colorless oil, 64 mg, 68% isolated yield); ¹H NMR (400 MHz, CDCl₃) δ 4.20–4.08 (m, 2H), 4.08–3.93 (m, 2H), 2.04–1.92 (m, 1H), 1.50–1.14 (m, 15H), 0.97 (s, 9H), 0.92 (s, 9H), 0.85–0.77 (m, 3H); ¹³C{¹H} NMR (101 MHz, CDCl₃) δ 78.5, 71.3, 37.6, 33.3, 31.9, 29.5, 29.3, 29.1, 27.4, 26.9, 24.5, 22.8, 22.7, 19.9, 14.1; IR 2927, 1473, 1133, 825 cm⁻¹; HRMS (ESI) calcd for C₂₀H₄₂IO₂Si⁺ 469.1993, found 469.1993 (MH⁺).



(±)-2,2-Di-tert-butyl-5-iodo-4-isobutyl-1,3,2-dioxasilinane (**32**). Synthesized using protocol B; single diastereomer; purified using 100% benzene on Florisil (colorless oil, 52 mg, 65%); ¹H NMR (400 MHz, chloroform-d) δ 4.28–4.12 (m, 3H), 3.97–4.05 (m, 1H), 2.00–1.84 (m, 2H), 1.44–1.37 (m, 1H), 1.05 (s, 9H), 0.99 (s, 9H), 0.96 (d, J = 6.5 Hz, 3H), 0.94 (d, J = 6.3 Hz, 3H); ¹³C{¹H} NMR (101 MHz, chloroform-*d*) δ 77.2, 71.2, 46.8, 34.1, 27.4, 26.9, 24.3, 23.7, 22.8, 21.1, 19.8; IR 2957, 1364, 903 cm⁻¹; HRMS (ESI) calcd for C₁₅H₃₂IO₂Si⁺ 399.1216, found 399.1253 (MH⁺).



2,2-Di-tert-butyl-5-iodo-4-isopentyl-1,3,2-dioxasilinane (**33**). Synthesized using protocol B; purified using 100% benzene on Florisil; single diastereomer (colorless oil, 73 mg, 89%); ¹H NMR (400 MHz, chloroform-*d*) δ 4.29–4.02 (m, 4H), 2.14–2.04 (m, 1H), 1.63–1.46 (m, 2H), 1.43–1.26 (m, 2H), 1.05 (s, 9H), 1.00 (s, 9H), 0.93 (d, *J* = 4.9 Hz, 3H), 0.91 (d, *J* = 4.8 Hz, 3H); ¹³C{¹H} NMR (101 MHz, chloroform-*d*) δ 78.7, 71.2, 35.4, 33.6, 33.3, 27.6, 27.4, 26.9, 23.0, 22.8, 22.2, 19.9; IR 2956, 1137, 896 cm⁻¹; HRMS (ESI) calcd for C₁₆H₃₄IO₂Si⁺ 413.1373, found 413.1370 (MH⁺).



2,2-Di-tert-butyl-5-iodo-4-isopropyl-1,3,2-dioxasilinane (34). Synthesized using protocol B; purified using benzene on Florisil (light yellow semisolid, 45 mg, 58% isolated yield); single diastereomer; ¹H NMR (400 MHz, CDCl₃) δ 4.32 (dd, J = 10.4, 4.2 Hz, 1H), 4.24 (t, J = 10.7 Hz, 1H), 4.21–4.12 (m, 1H), 4.02 (dd, J = 10.1, 2.0 Hz, 1H), 2.34 (pd, J = 6.8, 2.0 Hz, 1H), 1.07 (s, 9H), 1.04 (d, J = 6.4 Hz, 12H), 0.87 (d, J = 6.7 Hz, 3H); ¹³C{¹H} NMR (101 MHz, CDCl₃) δ 81.7, 71.8, 33.0, 31.8, 27.6, 26.9, 23.0, 20.2, 20.0, 13.2; IR 2960, 1076, 1028, 764 cm⁻¹; HRMS (ESI) calcd for C₁₄H₃₀IO₂Si⁺ 385.1060, found 385.1052 (MH⁺).



(±) 4-sec-Butyl-2,2-di-tert-butyl-5-iodo-1,3,2-dioxasilinane (**35**). Synthesized using protocol B; purified using 100% benzene on Florisil; ~1:1 mixture of diastereomers (colorless oil, 38 mg, 48%); ¹H NMR (400 MHz, chloroform-d) δ 4.36–4.27 (m, 1H), 4.27–4.14 (m, 2H), 4.08–4.00 (m, 1H), 2.07 (dddd, J = 18.4, 8.8, 5.1, 1.9 Hz, 1H), 1.56–1.46 (m, 1H), 1.46–1.34 (m, 1H), 1.24–1.14 (m, 1H), 1.07 (s, 4H), 1.06 (s, 5H), 1.04 (s, 1H), 1.03 (s, 4H), 1.02 (s, 5H), 0.97 (m, 3H), 0.87 (d, J = 6.7 Hz, 1H); ¹³C{¹H} NMR (101 MHz, chloroform-d) δ 82.6, 79.8, 71.9, 71.8, 39.8, 39.7, 31.6, 31.5, 27.6, 27.5, 27.0, 26.9, 26.8, 23.0, 20.4, 20.2, 16.5, 12.0, 11.7, 11.4; IR 2859, 1474, 939 cm⁻¹; HRMS (ESI) calcd for C₁₅H₃₂IO₂Si⁺ 399.1216, found 399.1161 (MH⁺).



2,2-Di-tert-butyl-4-cyclohexyl-5-iodo-1,3,2-dioxasilinane (**36**). Synthesized using protocol B; purified using benzene on Florisil (colorless semisolid, 59 mg, 70% isolated yield); single diastereomer; ¹H NMR (400 MHz, CDCl₃) δ 4.34–4.17 (m, 3H), 3.98 (dt, *J* = 8.1, 2.1 Hz, 1H), 2.00 (td, *J* = 5.3, 2.5 Hz, 1H), 1.86–1.74 (m, 2H), 1.70 (dt, *J* = 12.6, 2.8 Hz, 1H), 1.59 (dd, *J* = 8.4, 3.2 Hz, 1H), 1.53 (td, *J* = 9.4, 3.4 Hz, 2H), 1.40–1.12 (m, 4H), 1.06 (s, 9H), 1.03 (s, 9H); ¹³C{¹H} NMR (101 MHz, CDCl₃) δ 81.6, 71.8, 43.5, 31.1, 30.2, 27.6, 27.0, 26.5, 26.4, 26.0, 23.8, 23.0, 20.2; IR 2930, 1072, 1001, 975 cm⁻¹; HRMS (ESI) calcd for C₁₇H₃₄IO₂Si⁺ 425.1367, found 425.1358 (MH⁺).



2,2-Di-tert-butyl-5-iodo-4-(tetrahydro-2H-pyran-4-yl)-1,3,2dioxasilinane (**37**). Synthesized using protocol B; purified using a gradient of 0–40% EtOAc/benzene on Florisil; single diastereomer (light yellow oil, 64 mg, 75% isolated yield); ¹H NMR (400 MHz, CDCl₃) δ 4.23 (dd, *J* = 10.1, 3.9 Hz, 1H), 4.19–4.03 (m, 2H), 4.01–3.90 (m, 3H), 3.43–3.27 (m, 2H), 2.17 (ttd, *J* = 11.8, 3.7, 2.0 Hz, 1H), 1.92– 1.79 (m, 1H), 1.66–1.52 (m, 1H), 1.32 (dddt, *J* = 13.3, 11.5, 3.8, 2.1 Hz, 2H), 0.98 (s, 9H), 0.93 (s, 9H). ¹³C{¹H} NMR (101 MHz, CDCl₃) δ 80.5, 71.6, 68.0, 67.7, 40.5, 30.1, 29.5, 27.6, 26.9, 23.9, 23.0, 20.2; IR 2857, 1163, 1080, 825 cm⁻¹; HRMS (ESI) calcd for C₁₆H₃₂IO₃Si⁺ 427.1166, found 427.1162 (MH⁺).



2,2-Di-tert-butyl-5-iodo-1,3,2-dioxasilinan-4-yl)piperidine-1-carboxylate (**38**). Synthesized using protocol B; purified using 100% benzene on Florisil; single diastereomer (colorless oil, 51 mg, 48%); ¹H NMR (400 MHz, chloroform-*d*) δ 4.32–4.10 (m, 5H), 4.02 (dd, *J* = 10.1, 2.0 Hz, 1H), 2.70 (dd, *J* = 25.1, 13.4 Hz, 2H), 2.12 (ddddd, *J* = 13.6, 11.6, 9.7, 4.9, 2.0 Hz, 1H), 1.68 (dd, *J* = 28.2, 13.7 Hz, 1H), 1.52–1.45 (m, 3H), 1.47 (s, 9H), 1.03 (s, 9H), 0.98 (s, 9H); ¹³C{¹H} NMR (101 MHz, chloroform-*d*) δ 154.9, 80.5, 79.3, 71.6, 43.9, 41.4, 30.3, 28.4, 27.5, 26.9, 23.0, 22.9, 20.1; IR 2933, 1423, 923 cm⁻¹; HRMS (ESI) calcd for C₂₁H₄₁INO₄Si⁺ 526.1850, found 526.1891 (MH⁺).



2,2-Di-tert-butyl-5-iodo-4-methylcyclohexyl)-1,3,2-dioxasilinane (**39**). Synthesized using protocol B; purified using benzene on Florisil; single diastereomer (colorless oil, 63 mg, 72% yield); ¹H NMR (400 MHz, CDCl₃) δ 4.24–4.09 (m, 3H), 3.91 (dt, *J* = 8.8, 2.0 Hz, 1H), 1.88–1.78 (m, 1H), 1.67 (ddt, *J* = 13.6, 5.9, 1.9 Hz, 2H), 1.54–1.40 (m, 3H), 1.19 (dtt, *J* = 12.2, 9.0, 5.6 Hz, 3H), 0.96 (s, 9H), 0.92 (s, 9H), 0.94–0.84 (m, 1H), 0.81 (d, *J* = 6.5 Hz, 3H); ¹³C{¹H} NMR (101 MHz, CDCl₃) δ 81.3, 71.8, 42.5, 35.0, 34.6, 32.7, 31.3, 30.0, 27.6, 27.0, 23.5, 23.0, 22.6, 20.2; IR 2928, 1455, 1117, 825 cm⁻¹; HRMS (ESI) calcd for C₁₈H₃₆IO₂Si⁺ 439.1524, found 439.1516 (MH⁺).



2,2-Di-tert-butyl-5-iodo-4-((R)-1,4 dioxaspiro[4.5]decan-2-yl)-1,3,2-dioxasilinane (**40**). Synthesized using protocol B; purified using a gradient of 0 to 5% EtOAc/hexanes on Florisil; single diastereomer (colorless oil, 34 mg, 35% yield); ¹H NMR (400 MHz, CDCl₃) δ 4.45 (td, J = 6.7, 3.6 Hz, 1H), 4.30 (dd, J = 10.7, 3.6 Hz, 1H), 4.22–4.10 (m, 2H), 4.00–3.92 (m, 2H), 3.81 (td, J = 10.6, 5.2 Hz, 1H), 1.72–1.61 (m, 1H), 1.61–1.46 (m, 7H), 1.33 (s, 2H), 0.99 (s, 9H), 0.93 (s, 9H); ¹³C{¹H} NMR (101 MHz, CDCl₃) δ 110.3, 79.2, 77.5, 71.6, 63.7, 35.7, 35.6, 27.5, 26.9, 26.4, 25.2, 24.0, 23.8, 23.0, 20.1; IR 2933, 1110, 1058, 825 cm⁻¹; HRMS calculated for C₁₉H₃₆IO₄Si⁺ 483.1422, found 483.1414 (MH⁺).



2,2-Di-tert-butyl-4-(2,6-dimethylheptyl)-5-iodo-1,3,2-dioxasilinane (41). Synthesized using protocol C; purified using 100% benzene on Florisil; ~1:1 mixture of diastereomers (colorless oil, 61 mg, 65%); ¹H NMR (400 MHz, chloroform-*d*) δ 4.29–4.15 (m, 3H), 4.06–3.99 (m, 1H), 2.03 (ddd, J = 13.6, 8.9, 2.1 Hz, 1.4H), 1.87–1.76 (m, 0.6H), 1.60–1.50 (m, 1H), 1.47–1.37 (m, 1H), 1.37–1.31 (m, 1H), 1.30–1.22 (m, 2H), 1.20–1.13 (m, 2H), 1.12–1.07 (m, 1H), 1.05 (s, 9H), 0.99 (s, 9H), 0.95 (d, J = 6.8 Hz, 1.8H), 0.92 (d, J = 6.2 Hz, 1.2H), 0.89 (d, J = 1.2 Hz, 3H), 0.87 (d, J = 1.0 Hz, 3H); ¹³C{¹H} NMR (101 MHz, chloroform-*d*) δ 71.2, 71.2, 45.2, 44.7, 39.3, 39.1, 37.9, 35.6, 34.3, 29.3, 28.7, 27.9, 27.9, 27.44, 27.42, 26.9, 24.7, 24.4, 22.84, 22.81, 22.74, 22.70, 22.66, 22.59, 20.7, 19.8, 19.0; IR 2859, 1474, 906 cm⁻¹; HRMS (ESI) calcd for C₂₀H₄₂IO₂Si⁺ 469.1999, found 469.2005 (MH⁺).



2,2-Di-tert-butyl-4-ethyl-5-iodo-1,3,2-dioxasilinane-6-d (42). Synthesized using protocol A; purified using benzene on Florisil followed by eluting with 20% EtOAc/hexanes on a small plug of silica gel; mixture of diastereomers; (light yellow semisolid, 46 mg, 62% isolated yield); ¹H NMR (400 MHz, CDCl₃) δ 4.18–4.05 (m, 1H), 4.04–3.94 (m, 2H), 2.03 (dqd, *J* = 14.8, 7.4, 1.8 Hz, 1H), 1.58–1.42 (m, 1H), 0.97 (s, 9H), 0.91 (d, *J* = 7.1 Hz, 12H); ¹³C{¹H} NMR (101 MHz, CDCl₃) δ 79.5, 71.1–70.5 (m), 32.5, 30.6, 27.4, 26.9, 22.8, 19.9, 8.8; IR 2961, 1473, 1135, 827 cm⁻¹; HRMS (ESI) calcd for C₁₃H₂₇DIO₂Si⁺ 372.0961, found 372.0959 (MH⁺).



2,2-Di-tert-butyl-4-hexyl-5-iodo-1,3,2-dioxasilinane-6-d (43). Synthesized using protocol B; purified using benzene on Florisil; mixture of diastereomers (light yellow semisolid, 57 mg, 67% isolated yield); ¹H NMR (400 MHz, CDCl₃) δ 4.25–4.15 (m, 1H), 4.11 (ddd, J = 10.2, 7.8, 2.3 Hz, 1H), 4.08–4.00 (m, 1H), 2.13–1.99 (m, 1H), 1.57–1.45 (m, 2H), 1.38–1.19 (m, 7H), 1.04 (s, 9H), 0.99 (s, 9H), 0.92–0.87 (m, 3H); ¹³C{¹H} NMR (101 MHz, CDCl₃) δ 78.7, 71.3–70.7 (m), 37.7, 33.3, 31.9, 29.0, 27.6, 27.0, 24.6, 23.0, 22.7, 20.0, 14.2; IR 2957, 1473, 1088, 827 cm⁻¹; HRMS (ESI) calcd for C₁₇H₃DIO₂Si⁺ 428.1587, found 428.1578 (MH⁺).



2,2-Di-tert-butyl-5-iodo-4-phenyl-1,3,2-dioxasilinane (44). Synthesized using protocol C; purified using 100% benzene on Florisil; single diastereomer (colorless oil, 66 mg, 79%); ¹H NMR (400 MHz, chloroform-*d*) δ 7.48–7.35 (m, 5H), 5.13 (d, *J* = 9.8 Hz, 1H), 4.48–4.30 (m, 3H), 1.14 (s, 18H); ¹³C{¹H} NMR (101 MHz, chloroform-*d*) δ 142.4, 128.4, 128.1, 127.3, 82.0, 71.6, 34.2, 27.5, 27.0, 23.0, 20.2; IR 2859, 1471, 903 cm⁻¹; HRMS (ESI) calcd for C₁₇H₂₇IO₂SiNa⁺441.0717, found 441.0669 (MNa⁺).



2,2-Di-tert-butyl-4-(4-fluorophenyl)-5-iodo-1,3,2-dioxasilinane (**45**). Synthesized using protocol B; purified using 100% benzene on Florisil; single diastereomer (colorless oil, 61 mg, 70%); ¹H NMR (400 MHz, chloroform-*d*) δ 7.46–7.35 (m, 2H), 7.14–7.03 (m, 2H), 5.11 (d, *J* = 10.3 Hz, 1H), 4.47–4.24 (m, 3H), 1.13 (s, 9H), 1.12 (s, 9H); ¹³C{¹H} NMR (101 MHz, chloroform-*d*) δ 162.6 (d, *J* = 246.7 Hz), 138.4, 128.9 (d, *J* = 8.1 Hz), 115.0 (d, *J* = 21.3 Hz), 81.2, 71.5, 34.2, 27.5, 27.0, 23.0, 20.1; IR 2859, 1471, 1009 cm⁻¹; HRMS (ESI) calcd for C₁₇H₂₇FIO₂Si⁺ 437.0809, found 437.0796 (MH⁺).



4-(4-Bromophenyl)-2,2-di-tert-butyl-5-iodo-1,3,2-dioxasilinane (**46**). Synthesized using protocol B; purified using benzene on Florisil; single diastereomer (colorless oil, 79 mg, 80% yield); ¹H NMR (400 MHz, CDCl₃) δ 7.47–7.33 (m, 2H), 7.22–7.12 (m, 2H), 4.94 (d, J = 10.3 Hz, 1H), 4.34–4.21 (m, 2H), 4.13 (td, J = 10.4, 5.3 Hz, 1H), 0.99 (s, 9H), 0.98 (s, 9H); ¹³C{¹H} NMR (101 MHz, CDCl₃) δ 141.4, 131.3, 129.0, 122.3, 81.4, 71.5, 33.6, 27.5, 27.0, 23.0, 20.2; IR 2944, 1475, 1110, 827 cm⁻¹; HRMS (ESI) calcd for C₁₇H₂₇BrIO₂Si⁺ 497.0003, found 496.9971 (MH⁺).



4-(2,2-di-tert-butyl-5-iodo-1,3,2-dioxasilinan-4-yl)phenyl)morpholine (**47**). Synthesized using protocol C; purified using 100% benzene on Florisil; single diastereomer (colorless oil, 50 mg, 50%); ¹H NMR (400 MHz, chloroform-*d*) δ 7.34 (d, *J* = 8.8 Hz, 2H), 6.94 (d, *J* = 8.2 Hz, 2H), 5.10–4.97 (m, 1H), 4.47–4.31 (m, 3H), 3.95– 3.85 (m, 4H), 3.22 (dd, *J* = 5.8, 3.9 Hz, 4H), 1.12 (s, 9H), 1.11 (s, 9H); ¹³C{¹H} NMR (101 MHz, chloroform-*d*) δ 151.0, 134.0, 128.1, 114.9, 81.5, 71.5, 66.8, 49.0, 34.9, 27.5, 27.0, 23.0, 20.1; IR 2857, 1101, 932 cm⁻¹; HRMS (ESI) calcd for C₂₁H₃₅INO₃Si⁺ 504.1431, found 504.1426 (MH⁺).



4-(*Benzo*[*b*]*thiophene-3-yl*)-2,2-*di-tert-butyl*-5-*iodo*-1,3,2-*dioxa-silinane* (**48**). Synthesized using protocol C; purified using 100% benzene on Florisil; single diastereomer (colorless oil, 37 mg, 39%); ¹H NMR (400 MHz, chloroform-*d*) δ 8.01 (dd, *J* = 7.5, 1.3 Hz, 1H), 7.95–7.88 (m, 1H), 7.48–7.26 (m, 3H), 5.61 (d, *J* = 10.6 Hz, 1H), 4.70 (dt, *J* = 10.5, 7.9 Hz, 1H), 4.54–4.42 (m, 2H), 1.17 (s, 9H), 1.08 (s, 9H); ¹³C{¹H} NMR (101 MHz, chloroform-*d*) δ 140.3, 137.9, 137.8, 124.4, 124.3, 123.9, 122.8, 122.5, 75.5, 71.5, 31.3, 27.5, 27.0, 23.0, 20.0; IR 2833, 1428, 1007 cm⁻¹; HRMS calcd for C₁₉H₂₈IO₂SSi⁺ 475.0624, found 475.0632 (MH⁺).



2,2-Di-tert-butyl-5-iodo-1,3,2-dioxasilinan-4-yl)methyl acetate (49). Synthesized using protocol B; purified using a gradient of 0 to 100% acetone/DCM on Florisil followed by a gradient of 0–100% acetonitrile in 0.1% TFA-H₂O on a RediSep Prep C18 column (100 Å, 5 μ m, length 250 mm, i.d.: 20 mm, flow rate of 15 mL/min); single diastereomer (light yellow oil, 60 mg, 72% yield); ¹H NMR (400 MHz, CDCl₃) δ 4.45 (dd, *J* = 11.8, 2.7 Hz, 1H), 4.27 (dd, *J* = 11.4, 3.6 Hz, 1H), 4.21 (dd, *J* = 11.8, 6.0 Hz, 1H), 4.12 (ddd, *J* = 7.6, 5.6, 3.6 Hz, 1H), 4.07–3.98 (m, 2H), 2.05 (s, 3H), 0.98 (s, 9H), 0.97 (s, 9H); ¹³C{¹H} NMR (101 MHz, CDCl₃) δ 171.4, 71.5, 67.9, 66.2,

34.4, 27.5, 27.4, 20.9, 20.7, 20.5; IR 3442, 2947, 1730, 1246, 829 cm $^{-1}$; HRMS (ESI) calcd for $\rm C_{14}H_{28}IO_4Si^+$ 415.0796, found 415.0788 (MH⁺).



2,2-Di-tert-butyl-5-iodo-1,3,2-dioxasilinan-4-yl)methyl Benzoate (**50**). Synthesized using protocol B; purified using a gradient of 0– 50% acetone/DCM on Florisil followed by preparative TLC; single diastereomer (light yellow oil, 34 mg, 36% yield); ¹H NMR (400 MHz, CDCl₃) δ 8.10–7.99 (m, 2H), 7.62–7.54 (m, 1H), 7.49–7.40 (m, 2H), 4.78 (dd, *J* = 11.9, 2.7 Hz, 1H), 4.54 (dd, *J* = 11.9, 5.8 Hz, 1H), 4.38 (dd, *J* = 11.4, 3.7 Hz, 1H), 4.28 (ddd, *J* = 7.4, 5.7, 3.7 Hz, 1H), 4.19 (ddd, *J* = 7.4, 5.8, 2.7 Hz, 1H), 4.14 (dd, *J* = 11.3, 5.7 Hz, 1H), 1.05 (s, 9H), 1.04 (s, 9H); ¹³C{¹H} NMR (101 MHz, CDCl₃) δ 167.1, 133.5, 129.9, 129.7, 128.6, 71.8, 68.5, 66.3, 34.8, 27.6, 27.5, 20.8, 20.6; IR 3447, 2933, 1704, 1279, 827 cm⁻¹; HRMS (ESI) calcd for C₁₉H₃₀IO₄Si⁺477.0953, found 477.0985 (MH⁺).



2,2-Di-tert-butyl-5-iodo-4-phenethyl-1,3,2-dioxasilinane (51). Synthesized using protocol B; purified using a gradient of 0–10% EtOAc in hexanes on silica gel; single diastereomer (light yellow solid, 69 mg, 77% isolated yield); ¹H NMR (400 MHz, CDCl₃) δ 7.25–7.19 (m, 2H), 7.17–7.09 (m, 3H), 4.20–4.14 (m, 1H), 4.14–4.06 (m, 1H), 4.03–3.98 (m, 2H), 2.79 (ddd, *J* = 14.1, 9.7, 4.6 Hz, 1H), 2.65 (ddd, *J* = 13.6, 9.4, 7.3 Hz, 1H), 2.37 (dddd, *J* = 13.6, 9.3, 7.3, 1.7 Hz, 1H), 1.81–1.66 (m, 1H), 0.97 (s, 9H), 0.94 (s, 9H); ¹³C{¹H} NMR (101 MHz, CDCl₃) δ 141.8, 128.6, 128.3, 125.8, 77.7, 71.1, 39.4, 32.7, 31.0, 27.4, 27.0, 22.8, 19.9; IR 2931, 1174, 1042, 825 cm⁻¹; HRMS (ESI) calcd for C₁₉H₃₂IO₂Si⁺ 447.1211, found 447.1208 (MH⁺).



2,2-Di-tert-butyl-5-iodo-1,3,2-dioxasilinan-4-yl)pyridine (52). Synthesized using protocol C; purified using 100% benzene on Florisil; single diastereomer (colorless oil, 42 mg, 50%); ¹H NMR (400 MHz, chloroform-*d*) δ 8.61 (d, *J* = 2.3 Hz, 1H), 8.51 (dd, *J* = 4.8, 1.7 Hz, 1H), 7.65 (dt, *J* = 7.8, 1.9 Hz, 1H), 7.30–7.17 (m, 1H), 5.06 (d, *J* = 10.4 Hz, 1H), 4.39–4.26 (m, 2H), 4.19 (td, *J* = 10.3, 5.6 Hz, 1H), 1.02 (s, 9H), 1.02 (s, 9H); ¹³C{¹H} NMR (101 MHz, chloroform-*d*) δ 149.7, 149.2, 137.7, 134.5, 123.1, 79.8, 71.4, 33.2, 27.5, 26.9, 23.0, 20.1; IR 2859, 1471, 937 cm⁻¹; HRMS (ESI) calcd for C₁₆H₂₇INO₂Si⁺ 420.0856, found 420.0845 (MH⁺).



2,2-Di-tert-butyl-5-iodo-4,4-dimethyl-1,3,2-dioxasilinane (53). Synthesized using protocol B; purified using a gradient of 0–10% EtOAc in hexanes on silica gel (light yellow semisolid, 59 mg, 80% isolated yield); ¹H NMR (400 MHz, CDCl₃) δ 4.29 (dd, J = 11.8, 3.8 Hz, 1H), 4.24–4.15 (m, 1H), 4.06 (dd, J = 11.1, 3.9 Hz, 1H), 1.50 (s, 3H), 1.43 (s, 3H), 0.94 (s, 9H), 0.93 (s, 9H); ¹³C{¹H} NMR (101 MHz, CDCl₃) δ 75.2, 67.7, 37.1, 31.9, 27.3, 26.3, 21.5, 20.3; IR 2967, 1475, 1165, 825 cm⁻¹; HRMS (ESI) calcd for C₁₃H₂₈IO₂Si⁺ 371.0898, found 371.0899 (MH⁺).

Note



2,2-Di-tert-butyl-4,4-diethyl-5-iodo-1,3,2-dioxasilinane (54). Synthesized using protocol B; purified using 100% benzene on Florisil (colorless oil, 47 mg, 59%); ¹H NMR (400 MHz, chloroform-d) δ 4.54 (dd, J = 11.8, 4.5 Hz, 1H), 4.35 (t, J = 11.5 Hz, 1H), 4.16 (dd, J = 11.2, 4.5 Hz, 1H), 2.04 (dt, J = 14.7, 7.3 Hz, 1H), 1.89 (dqd, J = 14.6, 7.5, 2.4 Hz, 2H), 1.65 (dq, J = 14.8, 7.5 Hz, 1H), 1.05 (s, 9H), 1.03 (s, 9H), 1.06–0.98 (m, 6H); ¹³C{¹H} NMR (101 MHz, chloroform-d) δ 77.8, 67.3, 35.2, 32.4, 28.4, 27.9, 27.3, 21.6, 21.0, 8.2, 8.2; IR 2860, 1475, 1145 cm⁻¹; HRMS (ESI) calcd for C₁₅H₃₂IO₂Si⁺ 399.1216, found 399.1181 (MH⁺).



2,2-Di-tert-butyl-5-iodo-4-methyl-4-(4,8,12-trimethyltridecyl)-1,3,2-dioxasilinane (**55**). Synthesized using protocol B; purified using benzene on Florisil; mixture of diastereomers (light yellow oil, 81 mg, 70% yield); ¹H NMR (400 MHz, CDCl₃) δ 4.32–4.19 (m, 2H), 4.06 (dd, *J* = 8.9, 1.7 Hz, 1H), 1.84 (tdd, *J* = 13.1, 11.1, 4.6 Hz, 1H), 1.55– 0.97 (m, 23H), 0.94 (d, *J* = 4.6 Hz, 18H), 0.79 (dd, *J* = 8.4, 6.6 Hz, 12H); ¹³C{¹H} NMR (101 MHz, CDCl₃) δ 76.6, 67.6, 44.2, 44.1, 39.4, 37.52, 37.50, 37.48, 37.45, 37.34, 37.28, 37.23, 37.21, 32.84, 32.82, 32.6, 32.5, 28.0, 27.5, 27.4, 24.83, 24.82, 24.48, 24.42, 23.79, 23.77, 22.75, 22.65, 21.4, 20.4, 20.0, 19.9, 19.83, 19.80, 19.77, 19.70; IR 2859, 1377, 1464, 1080, 825 cm⁻¹; HRMS (ESI) calcd for C₂₈H₅₇INaO₂Si⁺ 603.3065, found 603.3049 (MNa⁺).



2,2-Di-tert-butyl-5-iodo-1,3,9-trioxa-2-silaspiro[5.5]undecane (**56**). Synthesized using protocol B; purified using 100% benzene on Florisil (colorless oil, 36 mg, 44%); ¹H NMR (400 MHz, chloroform-*d*) δ 4.35–4.16 (m, 2H), 4.06 (dd, *J* = 11.0, 3.4 Hz, 1H), 3.83–3.67 (m, 4H), 2.36–2.17 (m, 2H), 1.67 (dt, *J* = 13.6, 2.4 Hz, 1H), 1.34 (dt, *J* = 13.4, 2.3 Hz, 1H), 0.95 (s, 9H), 0.96 (s, 9H); ¹³C{¹H} NMR (101 MHz, chloroform-*d*) δ 73.4, 66.6, 63.8, 63.0, 38.5, 37.5, 33.5, 27.5, 27.2, 21.5, 20.3; IR 2861, 1471, 924 cm⁻¹; HRMS (ESI) calcd for C₁₅H₂₉IO₃SiNa⁺ 435.0828, found 435.0851 (MNa⁺).

V. Scale-up Procedure. A round-bottom flask was charged with stir bar, alkene substrate (870 mg, 2.97 mmol, 1 equiv), AgOTf (841 mg, 3.3 mmol, 1.3 equiv), and 25 mL of anhydrous DME. The reaction vial was immersed in a bath set to -15 °C. I₂ (830 mg, 3.2 mmol, 1.2 equiv) was added in one portion. A light-yellow precipitate formed immediately upon addition of AgOTf. The heterogeneous mixture was stirred for 2 h at -15 °C and then quenched by addition of aqueous saturated Na₂S₂O₃. The reaction mixture was diluted with ethyl acetate and transferred to a separatory funnel. The organic portion was collected, and the aqueous layer was extracted with two additional portions of ethyl acetate. The organic fractions were pooled, dried with MgSO₄, and concentrated under reduced pressure. The resulting residue was purified by chromatography on Florisil (100% benzene) to yield a light yellow solid (1.14 g, 2.72 mmol, 92% yield).

VI. Procedures for Derivatization Reactions. 44 (70 mg, 0.16 mmol) was dissolved in 6 mL of DCM. Tributyltin hydride (97 μ L, 0.36 mmol) was added, and the reaction was stirred for 12 h at 40 °C (oil bath). The reaction mixture was concentrated, and the resulting

residue was purified by chromatography on silica gel to yield 57 as a colorless oil (41 mg, 83%).



Compound **57**. Purified using a gradient of 0–10% EtOAc in hexanes on silica gel (colorless oil, 83%); ¹H NMR (400 MHz, chloroform-*d*) δ 7.48–7.35 (m, 4H), 7.35–7.26 (m, 1H), 5.22 (dd, *J* = 11.3, 2.3 Hz, 1H), 4.33 (ddd, *J* = 12.5, 11.1, 2.4 Hz, 1H), 4.21 (ddd, *J* = 11.0, 4.5, 2.0 Hz, 1H), 2.09 (dddd, *J* = 14.4, 12.5, 11.3, 4.5 Hz, 1H), 1.89 (dq, *J* = 14.4, 2.3 Hz, 1H), 1.15 (s, 9H), 1.13 (s, 9H); ¹³C{¹H} NMR (101 MHz, chloroform-*d*) δ 144.9, 128.3, 127.0, 125.0, 75.9, 64.7, 39.5, 27.5, 27.2, 22.9, 20.1; IR 2859, 1473, 886 cm⁻¹; HRMS (ESI) calcd for C₁₇H₂₉O₂Si⁺ 293.1937, found 293.1938 (MH⁺).

Compound 44 (70 mg, 0.16 mmol) was dissolved in 0.5 mL of DMF. To this solution were added sodium azide (0.32 mmol, 2 equiv) and 15-crown-5 (0.32 mmol, 2 equiv) at room temperature. The temperature of the reaction was gradually increased to 100 °C (oil bath) and kept at this temperature for 12 h with magnetic stirring. After consumption of starting material (followed by TLC), the reaction mixture was diluted with EtOAc and transferred to a separatory funnel. The organic layer was washed with cold water (3×3 mL). The organic layer was collected, dried over Na₂SO₄, and concentrated under reduced pressure. The resulting residue was purified by chromatography on silica gel to yield compound **58** (24 mg, 43%) as a colorless solid.



Compound **58**. Purified using benzene on Florisil; single diastereomer (colorless solid, 54%); ¹H NMR (400 MHz, chloroform-*d*) δ 7.46–7.35 (m, 5H), 5.46 (d, *J* = 2.0 Hz, 1H), 4.56 (dd, *J* = 12.5, 1.8 Hz, 1H), 4.39 (dd, *J* = 12.5, 2.0 Hz, 1H), 3.82 (q, *J* = 1.9 Hz, 1H), 1.20 (s, 9H), 1.14 (s, 9H); ¹³C{¹H} NMR (101 MHz, chloroform-*d*) δ 140.6, 128.2, 127.7, 125.7, 76.3, 66.1, 64.4, 27.7, 27.2, 23.5, 20.7; IR 2860, 1474, 889 cm⁻¹; HRMS (ESI) calcd for C₁₇H₂₈N₃O₂Si⁺ 334.1951, found 334.1960 (MH⁺).

TBAF in THF (1 M, 0.280 mL, 0.28 mmol) was added to compound 44 (40 mg, 0.09 mmol) in THF (2 mL) at 0 $^{\circ}$ C, and the reaction was warmed to room temperature over 16 h. Following this time, the reaction mixture was concentrated, and the resulting residue was purified by chromatography on silica gel to yield 59 (9 mg, 63%) as a colorless oil.



59

Compound **59**. Purified using a gradient of 0 to 20% EtOAc in hexanes on silica gel; single diastereomer (colorless oil, 63%); ¹H NMR (600 MHz, chloroform-*d*) δ 7.44–7.25 (m, 5H), 4.09 (dd, *J* = 12.8, 2.4 Hz, 1H), 3.97 (d, *J* = 2.1 Hz, 1H), 3.84 (dd, *J* = 12.8, 3.8 Hz, 1H), 3.27 (dt, *J* = 4.2, 2.4 Hz, 1H), 1.95 (s, 1H); ¹³C{¹H} NMR (101 MHz, chloroform-*d*) δ 136.6, 128.5, 128.3, 125.7, 62.3, 61.1, 55.5.

HF·pyridine (~70% HF–30% pyridine, 75 μ L) was added to compound 44 (40 mg, 0.09 mmol) in THF at 0 °C, and the mixture was stirred for 5 min. The reaction was quenched with saturated aqueous NaHCO₃ and transferred to a separatory funnel. The water layer was extracted with three portions of ethyl acetate. The organic layers were collected, pooled, and dried with Na₂SO₄. After concentration under reduced pressure, the resulting residue was

purified by chromatography on silica gel to yield 60 (13 mg, 49%) as a colorless oil.

OH OH

Compound **60**. Purified using a gradient of 0–40% EtOAc in hexanes on silica gel (colorless oil, 49%); ¹H NMR (400 MHz, chloroform-*d*) δ 7.47–7.32 (m, 5H), 5.08 (dd, *J* = 6.3, 2.5 Hz, 1H), 4.53–4.42 (m, 1H), 4.00 (dd, *J* = 12.3, 4.6 Hz, 1H), 3.91–3.78 (m, 1H), 2.75–2.5 (bs, 2H); ¹³C{¹H} NMR (101 MHz, chloroform-*d*) δ 140.8, 128.6, 128.5, 126.5, 78.5, 65.9, 41.3; IR 2926, 1455, 1002 cm⁻¹; HRMS (ESI) calcd for C₉H₁₁IO₂Na⁺ 300.9702, found 300.9744 (MNa⁺).

ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.joc.1c00872.

Expanded procedures, crystal structure data, NMR spectra and computational details (PDF)

Accession Codes

CCDC 2062814 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge via www.ccdc.cam.ac.uk/data_request/cif, or by emailing data_request@ccdc.cam.ac.uk, or by contacting The Cambridge Crystallographic Data Centre, 12 Union Road, Cambridge CB2 1EZ, UK; fax: +44 1223 336033.

AUTHOR INFORMATION

Corresponding Author

Shyam Sathyamoorthi – Department of Medicinal Chemistry, University of Kansas, Lawrence, Kansas 66047, United States; orcid.org/0000-0003-4705-7349; Email: ssathyam@ku.edu

Authors

- **Ranjeet A. Dhokale** Department of Medicinal Chemistry, University of Kansas, Lawrence, Kansas 66047, United States
- Frederick J. Seidl Independent Researcher, San Bruno, California 94066, United States; o orcid.org/0000-0001-9327-4753
- Anand H. Shinde Department of Medicinal Chemistry, University of Kansas, Lawrence, Kansas 66047, United States; o orcid.org/0000-0003-1966-8505
- Joel T. Mague Department of Chemistry, Tulane University, New Orleans, Louisiana 70118, United States

Complete contact information is available at: https://pubs.acs.org/10.1021/acs.joc.1c00872

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

This work was supported by start-up funding provided jointly by the University of Kansas Office of the Provost and the Department of Medicinal Chemistry, an NIH COBRE Chemical Biology of Infectious Diseases Research Project Grant (P20GM113117), and a New Faculty General Research Fund Grant.

REFERENCES

(1) Degennaro, L.; Trinchera, P.; Luisi, R. Recent Advances in the Stereoselective Synthesis of Aziridines. *Chem. Rev.* **2014**, *114*, 7881–7929.

(2) Overman, L. E.; Campbell, C. B. Hemiacetal mediated reactions. Directed synthesis of diols and acetals. *J. Org. Chem.* **1974**, *39*, 1474–1481.

(3) Sarraf, S. T.; Leighton, J. L. Oxymercuration of Homoallylic Alcohol Derived Hemiacetals: Diastereoselective Synthesis of Protected 1,3-Diols. *Org. Lett.* **2000**, *2*, 403-405.

(4) Oswald, J. P.; Woerpel, K. A. Cobalt-Catalyzed Intramolecular Silylperoxidation of Unsaturated Diisopropylsilyl Ethers. *J. Org. Chem.* **2019**, *84*, 7564–7574.

(5) Kotov, V.; Scarborough, C. C.; Stahl, S. S. Palladium-Catalyzed Aerobic Oxidative Amination of Alkenes: Development of Intra- and Intermolecular Aza-Wacker Reactions. *Inorg. Chem.* **2007**, *46*, 1910–1923.

(6) Wang, D.; Weinstein, A. B.; White, P. B.; Stahl, S. S. Ligand-Promoted Palladium-Catalyzed Aerobic Oxidation Reactions. *Chem. Rev.* 2018, *118*, 2636–2679.

(7) Thomas, A. A.; Nagamalla, S.; Sathyamoorthi, S. Salient features of the aza-Wacker cyclization reaction. *Chem. Sci.* **2020**, *11*, 8073–8088.

(8) Shinde, A. H.; Sathyamoorthi, S. Oxidative Cyclization of Sulfamates onto Pendant Alkenes. *Org. Lett.* **2020**, *22*, 896–901.

(9) Shinde, A. H.; Nagamalla, S.; Sathyamoorthi, S. N-arylated oxathiazinane heterocycles are convenient synthons for 1,3-amino ethers and 1,3-amino thioethers. *Med. Chem. Res.* **2020**, *29*, 1223–1229.

(10) Shinde, A. H.; Thomas, A. A.; Mague, J. T.; Sathyamoorthi, S. Highly Regio- and Diastereoselective Tethered Aza-Wacker Cyclizations of Alkenyl Phosphoramidates. *ChemRxiv* **2021**, DOI: 10.26434/ chemrxiv.14132177.v1.

(11) Shinde, A. H.; Sathyamoorthi, S. Tethered Silanoxymercuration of Allylic Alcohols. *Org. Lett.* **2020**, *22*, 8665–8669.

(12) Dhokale, R. A.; Seidl, F. J.; Sathyamoorthi, S. A Rearrangement of Allylic Silanols. *ChemRxiv* **2021**, DOI: 10.26434/chemrxiv.13679083.v1.

(13) Nakamura, E.; Inubushi, T.; Aoki, S.; Machii, D. Aerobic conversion of organic halides to alcohols. An oxygenative radical cyclization. J. Am. Chem. Soc. **1991**, 113, 8980–8982.

(14) Matier, C. D.; Schwaben, J.; Peters, J. C.; Fu, G. C. Copper-Catalyzed Alkylation of Aliphatic Amines Induced by Visible Light. J. Am. Chem. Soc. 2017, 139, 17707–17710.

(15) Lipshutz, B. H.; Wilhelm, R. S.; Kozlowski, J. A.; Parker, D. Substitution reactions of secondary halides and epoxides with higher order, mixed organocuprates, R2Cu(CN)Li2: synthetic, stereo-chemical, and mechanistic aspects. *J. Org. Chem.* **1984**, *49*, 3928–3938.

(16) Denmark, S. E.; Burk, M. T. Lewis base catalysis of bromo- and iodolactonization, and cycloetherification. *Proc. Natl. Acad. Sci. U. S. A.* **2010**, *107*, 20655.

(17) Laya, M.; Banerjee, A.; Cabrera, E. Iodolactonization: Past and Present Examples. *Curr. Org. Chem.* **2009**, *13*, 720–730.

(18) Nolsøe, J. M. J.; Hansen, T. V. Asymmetric Iodolactonization: An Evolutionary Account. *Eur. J. Org. Chem.* 2014, 2014, 3051–3065.
(19) Oderinde, M. S.; Hunter, H. N.; Bremner, S. W.; Organ, M. G.

Iodolactonization: Synthesis, Stereocontrol, and Compatibility Studies. *Eur. J. Org. Chem.* 2012, 2012, 175–182.

(20) Corey, E. J.; Weinshenker, N. M.; Schaaf, T. K.; Huber, W. Stereo-controlled synthesis of dl-prostaglandins F2.alpha. and E2. J. Am. Chem. Soc. **1969**, *91*, 5675–5677.

(21) Bedford, S. B.; Bell, K. E.; Fenton, G.; Hayes, C. J.; Knight, D. W.; Shaw, D. Iodoetherification of homoallylic alcohols: A stereo-selective approach to tetrahydrofurans. *Tetrahedron Lett.* **1992**, *33*, 6511–6514.

(22) Brimble, M. A.; Edmonds, M. K. Synthesis of bis-2,5-linked tetrahydrofurans via iodoetherification. *Tetrahedron* **1995**, *51*, 9995–10012.

(23) Lipshutz, B. H.; Barton, J. C. Reagent-based stereocontrol in formation of substituted tetrahydrofurans. J. Am. Chem. Soc. 1992, 114, 1084–1086.

(24) Campbell, M. J.; Johnson, J. S. Asymmetric Synthesis of (+)-Polyanthellin A. J. Am. Chem. Soc. 2009, 131, 10370–10371.

(25) Guindon, Y.; Slassi, A.; Ghiro, É.; Bantle, G.; Jung, G. Stereoselective silver triflate-mediated iodocyclization of carbamates. *Tetrahedron Lett.* **1992**, 33, 4257–4260.

(26) Cataldo, F. Iodine: A ring opening polymerization catalyst for tetrahydrofuran. *Eur. Polym. J.* **1996**, *32*, 1297–1302.

(27) Neese, F. The ORCA program system. Wiley Interdiscip. Rev.: Comput. Mol. Sci. 2012, 2, 73-78.

(28) Neese, F. Software update: the ORCA program system, version 4.0. Wiley Interdiscip. Rev.: Comput. Mol. Sci. 2018, 8, No. e1327.

(29) Becke, A. D. A new mixing of Hartree-Fock and local density-functional theories. *J. Chem. Phys.* **1993**, *98*, 1372–1377.

(30) Lee, C.; Yang, W.; Parr, R. G. Development of the Colle-Salvetti correlation-energy formula into a functional of the electron density. *Phys. Rev. B: Condens. Matter Mater. Phys.* **1988**, *37*, 785–789.

(31) Grimme, S.; Antony, J.; Ehrlich, S.; Krieg, H. A consistent and accurate ab initio parametrization of density functional dispersion correction (DFT-D) for the 94 elements H-Pu. *J. Chem. Phys.* 2010, 132, 154104.

(32) Grimme, S.; Ehrlich, S.; Goerigk, L. Effect of the damping function in dispersion corrected density functional theory. *J. Comput. Chem.* **2011**, 32, 1456–1465.

(33) Weigend, F. Accurate Coulomb-fitting basis sets for H to Rn. *Phys. Chem. Chem. Phys.* **2006**, *8*, 1057–1065.

(34) Weigend, F.; Ahlrichs, R. Balanced basis sets of split valence, triple zeta valence and quadruple zeta valence quality for H to Rn: Design and assessment of accuracy. *Phys. Chem. Chem. Phys.* **2005**, *7*, 3297–3305.

(35) Marenich, A. V.; Cramer, C. J.; Truhlar, D. G. Universal Solvation Model Based on Solute Electron Density and on a Continuum Model of the Solvent Defined by the Bulk Dielectric Constant and Atomic Surface Tensions. *J. Phys. Chem. B* **2009**, *113*, 6378–6396.

(36) Peterson, K. A.; Figgen, D.; Goll, E.; Stoll, H.; Dolg, M. Systematically convergent basis sets with relativistic pseudopotentials. II. Small-core pseudopotentials and correlation consistent basis sets for the post-d group 16–18 elements. *J. Chem. Phys.* **2003**, *119*, 11113–11123.

(37) Luh, T.-Y.; Hu, Z. Thorpe-Ingold effect in organosilicon chemistry. *Dalt. Trans.* 2010, 39, 9185–9192.